新浪科技讯 2月10日下午消息，近日新东方创始人、东方甄选董事长俞敏洪近日在直播间宣布，东方甄 选计划于今年正式成立电商培训学校。俞敏洪表示，开办电商培训的初衷，当前各地相关部门对电商非 常重视，常常说希望派人来培训一下。 他说，"其实我们也在摸索。但是我觉得，与其孤独地摸索，不如一起摸索。所以我们干脆在北京准备 成立一个电商学校，让各个地方派这些电商的运营人才、主播等，到北京去培训。因为北京人才聚集， 可以请到好多人才来讲课。" 据悉，早在去年年中，俞敏洪就曾经在直播中表示，有考虑做新东方电商学院的想法。他认为，现在做 电商直播的网红、主播，都需要一种文化培训。不是为了挣钱，而是为了让中国主播的整体水平得到一 个层次的提高，如果成立了，他会亲自去上课，也会让著名主播去上课。 责任编辑：何俊熹 ...

Market Performance - The three major U.S. stock indices closed higher, with the Dow Jones up 0.04%, the Nasdaq up 0.9%, and the S&P 500 up 0.47% [1] - Major technology stocks saw significant gains, with Oracle rising over 9%, Microsoft and Broadcom up over 3%, and Nvidia and Meta up over 2% [1] Sector Performance - Cryptocurrency mining companies, precious metals, and non-ferrous metals led the gains, with Vista Gold up over 14%, Hut 8 up over 7%, and Pan American Silver up over 6% [1] - Other notable performers included Alcoa and Royal Gold, both rising over 5%, and Southern Copper up over 4% [1] - Retail and insurance brokerage sectors faced declines, with Macy's and Kohl's both down over 5%, and the American Reinsurance Group down over 2% [1] Chinese Stocks - The Nasdaq Golden Dragon China Index rose 0.12%, with notable gains in Chinese concept stocks such as Kingsoft Cloud, Pony.ai, and JinkoSolar, which rose up to 3.79% [1] - Other gainers included Zai Lab up 2.44%, Huazhu up 1.66%, while companies like Yum China, XPeng, Ctrip, Bilibili, NIO, Li Auto, and New Oriental experienced declines, with New Oriental down 4.24% [1]

2月9日，美股三大指数集体低开，纳指跌0.37%，道指跌0.21%，标普500指数跌0.26%。 大型科技股涨跌不一，闪迪跌超4%，超威半导体跌近2%；甲骨文涨近5%。 | 名称 | 涨跌幅 现价 | | --- | --- | | 道琼斯工业平均 | -0.21% 50008.58 | | 纳斯达克指数 | -0.37% 22945.34c | | 标普500 | -0.26% 6914.06 | 热门中概股集体下跌，纳斯达克中国金龙指数跌0.7%，理想汽车、哔哩哔哩、新东方、蔚来跌超 3%，携程集团、百度集团、腾讯音乐、京东集团跌超1%。 | 名称 | 涨跌幅 ▲ | 现价 | | --- | --- | --- | | 理想汽车 | -3.80% | 18.250 | | 昨週歩1 | -3.30% | 30.490 | | 新东方 | -3.30% | 60.650 | | 劇来 | -3.08% | 4.885 | | 搜狐 | -2.57% | 15.939 | | 携程集团 | -1.95% | 58.240 | | 百度集团 | -1.64% | 143.540 | | 小马智行 | -1.3 ...

智通财经APP获悉，香港联交所最新资料显示，2月3日，第一北京投资有限公司减持新东方- S(09901)144.12万股，每股作价49.0174港元，总金额约为7064.39万港元。减持后最新持股数目约为1.88 亿股，最新持股比例为10.96%。 ...

香港联交所最新资料显示，2月3日，第一北京投资有限公司减持新东方-S(09901)144.12万股，每股作价 49.0174港元，总金额约为7064.39万港元。减持后最新持股数目约为1.88亿股，最新持股比例为 10.96%。 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it will outperform the overall market [1]. Core Insights - The report highlights that the commercialization of innovative drugs, combined with licensing income, is expected to lead to profitability for several companies in 2025, including BeiGene, Innovent Biologics, and others [1][9]. - The Pharma sub-sector is projected to achieve a revenue growth rate of 15-20% in 2025 for companies like Hansoh Pharmaceutical and China Biologic Products, with a significant revenue increase expected for 3SBio due to a major business development deal with Pfizer [2][10]. - The CXO sector is also expected to show strong performance, with companies like WuXi AppTec forecasting a revenue increase of approximately 15.84% and a net profit growth of about 102.65% in 2025 [3][11]. - In the medical services sector, the report notes that valuations are at historical lows, with a projected revenue growth of 13% for GuoShengTang in 2025, emphasizing the importance of overseas business expansion and AI integration in traditional Chinese medicine [4][12]. Summary by Sections Innovative Drugs - The report anticipates that several innovative drug companies will reach profitability in 2025 due to increased commercialization and business development income [9][15]. Pharma - The Pharma sub-sector is expected to see a revenue growth of 15-20% in 2025 for key players, with 3SBio projected to achieve over 100% growth due to a significant partnership with Pfizer [2][10]. CXO - WuXi AppTec is expected to report a revenue of approximately 454.56 billion RMB in 2025, with a net profit growth of around 102.65% [3][11]. Medical Services - GuoShengTang is projected to have a revenue growth of 13% in 2025, with a focus on overseas acquisitions and AI applications in traditional medicine [4][12].

新力量 New Force 第一上海研究部 research@firstshanghai.com 总第 4960 期 2026 年 2 月 6 日 星期五 研究观点 【公司研究】 新东方（EDU.US/9901.HK）FY26Q2 业绩表现超预期，全年收入指引上调 【公司评论】 四环医药(460.HK）：仿制药触底中，轩竹生物成功分拆，创新药进入收获期，惠升生 物布局糖尿病全管线也迎来成果兑现，医美肉毒素和新品大品种带动高速增长 评级变化 | 公司 | 评级 代码 | 目标价(港元） | | 2025年EPS(港元) | | | 2026年EPS(港元) | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 新 旧 | 新 旧 | 变动 | 新 | 旧 | 变动 | 新 | 旧 | 变动 | | 新东方（美元） | EDU 买入 买入 78.00 | 74.50 | 5% | 0.230 | 0.230 | 0% | 0.310 | 0.300 | 3% | 第一上海证券有限公司 香港中环德辅道中 71 号永安集团大厦 ...

Core Viewpoint - The Nasdaq Golden Dragon China Index saw an initial increase of 1.21%, indicating positive market sentiment towards Chinese stocks listed in the U.S. [1] Company Performance - NIO experienced a significant rise of 7.4% - Miniso increased by 5.4% - Yum China rose by 3.4% - Li Auto gained 2.8% - ZTO Express, Zai Lab, Bilibili, Baidu, and Kingsoft Cloud all saw increases of over 2% - Alibaba had a modest increase of 0.7% - Pony.ai declined by 1.2% - New Oriental fell by 2.8% [1] ETF Performance - KWEB ETF rose by 1.14% - CQQQ ETF increased by 0.7% - ASHR ETF decreased by 0.1% - ASHS ETF fell by 1.3% [1]

来源：中国网 2月3日，2025年"中国大学生自强之星"活动分享会在北京交通大学科学会堂举行。本次活动由共青团中 央基层建设部指导，中国青年报社、中国青少年发展基金会主办，新东方教育科技集团协办，聚焦立德 树人根本任务，深入挖掘在爱国奉献、道德弘扬、科技创新、自主创业、志愿公益、身残志坚、自立自 强等方面事迹突出的新时代大学生先进典型，树立青年榜样。本年度共产生1000名"中国大学生自强之 星"个人及100个"中国大学生自强之星科创团体"。 "中国大学生自强之星"评选活动于2007年启动，新东方先后共出资1亿元，在全国范围内寻访青年榜 样。十八年来，活动共产生1.5万余名"中国大学生自强之星"。值得一提的是，自2024年度首次增设"科 创团体"类别以来，该类别累计获奖团体已达200个。他们与个人获奖者共同构建起更为立体、多元的青 年榜样群像，展现出新时代大学生在科技创新与团队协作中的蓬勃朝气与担当精神。 分享会伊始，北京交通大学党委常委、副校长李国岫在致辞中指出，自强的学子"用很真实的奋斗诠释 着新时代青年的优秀"，他们将自信、自立、自强内化为人生信条，将个人奋斗融入了时代洪流。他强 调，学校通过"将外在的资 ...